Boosting Cytotoxic Antibodies against Cancer

Laurent Gauthier; Eric Vivier

doi:10.1016/j.cell.2020.02.025

Boosting Cytotoxic Antibodies against Cancer

Cell. 2020 Mar 5;180(5):822-824. doi: 10.1016/j.cell.2020.02.025.

Authors

Laurent Gauthier¹, Eric Vivier²

Affiliations

¹ Innate Pharma Research Laboratories, Innate Pharma, Marseille, France. Electronic address: laurent.gauthier@innate-pharma.fr.
² Innate Pharma Research Laboratories, Innate Pharma, Marseille, France; Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France; APHM, Hôpital de la Timone, Service d'Immunologie, Marseille-Immunopôle, Marseille, France.

PMID: 32142673
DOI: 10.1016/j.cell.2020.02.025

Abstract

Monoclonal antibodies (mAbs) targeting antigens expressed at the surface of tumor cells are widely used for cancer control in clinics, but these treatments need to be improved. Chew et al. show how an old drug, prochlorperazine, could be repurposed to enhance the efficacy of anti-tumor mAbs by increasing the cell-surface expression of tumor antigens.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal
Antibody-Dependent Cell Cytotoxicity*
Antigens, Neoplasm
Endocytosis
Humans
Neoplasms*

Substances

Antibodies, Monoclonal
Antigens, Neoplasm